News for Tarsus Pharmaceuticals, Inc. (TARS)

Summary Tarsus Pharmaceuticals Inc (TARS), a company dedicated to revolutionizing treatment through proven science and new technology, announced its participati

**media[559707]**

Comprehensive SWOT analysis based on Tarsus Pharmaceuticals Inc's latest SEC 10-K filing.Financial overview highlights a market capitalization of approximately

On February 25, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring an additional 2,000,000 shares of Acelyrin

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICLâ„¢) for vision correction

Net Product Sales: $180.1 million for the full year 2024.Q4 Product Sales: $66.4 million.Bottles Dispensed: 163,000 bottles for the full year 2024.Gross Margin

Feb 25, 2025 / 01:00PM GMTOperator Good morning and welcome to Tarsus this year in 2024 financial results conference call. As a reminder, this call is being rec

The following slide deck was published by Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals Inc (TARS) announced its financial results for the fourth quarter and full-year 2024, showcasing significant growth in net product sales

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 11.76% and 12.33%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Generated fourth quarter and full-year 2024 net product sales of XDEMVY® of $66.4 million and $180.1 million, respectively, during the first full year of launc

Tarsus Pharmaceuticals Inc (TARS) is set to release its Q4 2024 earnings on Feb 25, 2025. The consensus estimate for Q4 2024 revenue is $58.33 million, and the

On February 18, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring 5,298,328 shares of Acelyrin Inc. This acqu

Summary Tarsus Pharmaceuticals Inc (TARS), a biopharmaceutical company focused on innovative treatments, announced it will host a live webcast on February 25, 2

**media[546197]**

On February 7, 2025, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a significant transaction by acquiring 4,210,525 shares of Galapagos NV. This acqu

**media[528592]**

Tarsus Pharmaceuticals' lotilaner shows strong market performance for Demodex blepharitis, but cautious investment due to lack of near-term catalysts. Read more here.

The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.